Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Disease-modifying antirheumatic drugs.

L Ryan1, P Brooks

  • 1Department of Rheumatology, Royal Brisbane Hospital, Australia.

Current Opinion in Rheumatology
|May 18, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

SCANBIT facilitates identification of tumor cell populations in scRNAseq data using pseudobulked SNV calls.

bioRxiv : the preprint server for biology·2026
Same author

Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2023
Same author

Luck of the Microbiologist - A Retrospective Observational Cohort Study.

Irish medical journal·2023
Same author

Cementless versus cemented unicompartmental knee arthroplasty: a systematic review of comparative studies.

Musculoskeletal surgery·2023
Same author

Investigating Effects of Mentoring for Youth with Assault Injuries: Results of a Randomized-Controlled Trial.

Prevention science : the official journal of the Society for Prevention Research·2022
Same author

Drug mixtures and infusion technology.

Anaesthesia·2022
Same journal

New approaches to the management of cutaneous lupus.

Current opinion in rheumatology·2026
Same journal

"Updates in chronic nonbacterial osteomyelitis: emerging insights across the age spectrum".

Current opinion in rheumatology·2026
Same journal

Difficult-to-treat, complex-to-manage, treatment-refractory spondyloarthritis: semantics or substance?

Current opinion in rheumatology·2026
Same journal

Update on IgA nephropathy: implications for treatment in IgA vasculitis: a guide for rheumatologists.

Current opinion in rheumatology·2026
Same journal

Polyarticular juvenile idiopathic arthritis: insights from genetic studies on disease risk and pathogenesis.

Current opinion in rheumatology·2026
Same journal

Immune dysregulation in children with Down syndrome: clinical implications and emerging therapies.

Current opinion in rheumatology·2026
See all related articles

Early rheumatoid arthritis treatment with disease-modifying antirheumatic drugs prevents erosions. Methotrexate is a common drug, but dosage adjustments are needed for the elderly and those with kidney issues.

Area of Science:

  • Rheumatology
  • Immunology
  • Pharmacology

Background:

  • Early intervention in rheumatoid arthritis (RA) is crucial for preventing joint erosions.
  • Disease-modifying antirheumatic drugs (DMARDs) are standard for RA management.
  • Methotrexate is a widely used DMARD, often in combination therapies.

Purpose of the Study:

  • To review the current understanding of early RA treatment strategies.
  • To evaluate the efficacy and cost-effectiveness of DMARD combinations.
  • To identify optimal treatment regimens for preventing RA-related damage.

Main Methods:

  • Literature review of clinical trials and treatment guidelines for rheumatoid arthritis.
  • Analysis of cost-effectiveness data for various DMARD combinations.

Related Experiment Videos

  • Assessment of methotrexate dosage adjustments in specific patient populations.

    • Main Results:

    • Early DMARD treatment is essential for preventing rheumatoid arthritis erosions.
    • Methotrexate is a frequently used DMARD, requiring dose modification in elderly patients and those with renal impairment.
    • A combination of sulfasalazine, methotrexate, and reduced-dose prednisolone is cost-effective for RA treatment.

    Conclusions:

    • Early and aggressive treatment of rheumatoid arthritis with DMARDs is necessary to prevent erosions.
    • While methotrexate is a cornerstone therapy, careful dose management is vital.
    • Further research is needed to definitively establish the best combination therapy for rheumatoid arthritis, though some combinations show promise.